11/01/2019 21:30:00

InspireMD Receives Noncompliance Notice from NYSE American

TEL AVIV, Israel, Jan. 11, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that on January 7, 2019, the Company received a letter from NYSE American LLC (“NYSE American”) stating that it is not in compliance with the continued listing standards as set forth in Part 10, Section 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”) due to the Company’s current low selling share price.

The Company’s continued listing on the NYSE American is contingent upon the Company effecting a share consolidation or otherwise demonstrating a sustained improvement in its share price within a reasonable period of time but no later than July 7, 2019.

About InspireMD, Inc.

InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.

InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at https://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Contacts:

Craig Shore

Chief Financial Officer

InspireMD, Inc.

888-776-6804

craigs@inspiremd.com 

Jeremy Feffer

LifeSci Advisors, LLC

212-915-2568

jeremy@lifesciadvisors.com

inspiremd.png

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Jan
I:SP500
  Hejsa    Jeg har igen vedlagt vores langsigtede konjunkturmodel med de ledende indikatorer i USA, ..
39
17 Jan
PNDORA
Jeg vil bare henlede opmærksomheden paa Lars Christensens artikel omkring "Short Selling", direkte h..
37
18 Jan
PNDORA
En stor tak til alle jer, der har givet mig en like (ialt 32). Det er dejligt at vide, at vi er mang..
20
19 Jan
I:NDX
Har lige opdaget at man kan trykke på en knap og sende en like. Men hvad skal man bruge det til? Alt..
18
19 Jan
 
Jeg deltog i går i en spørgeseance med CEO for Euronav Paddy Rodgers. Euronav er et pure play på råo..
18
16 Jan
VWS
Din indsigt i verdensfirmaet Vestas er forbløffende!
14
22 Jan
DANSKE
Det kan jo aldrig falde tilbage på en bank eller dens aktionærer at der er en flok institionelle inv..
13
22 Jan
GOMX
Update fra SASg i morges: 29 customers signed with expected annualised revenues of $10 - $12M from 1..
13
18 Jan
ROV
Ja, og de to ovenstående kommentarer er i den grad med til at forringe og forsimple debatniveauet he..
13
17 Jan
PNDORA
Udfordringen er, at der hele tiden sker en bekræftigelse af at Pandoras fald er faldende uden nogle ..
13

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
LoRa Alliance Passes 100 LoRaWAN™ Network Operator Milestone with Coverage in 100 Countries
2
General Cannabis Continues Expansion with Latest Office Opening in Los Angeles and Renovation of 15,000 Square Foot Denver Headquarters
3
Distilled Identity and Emerge Announce Technology Partnership to Solve Global Identity Crisis for Refugees
4
Bloomington-Normal Association of Realtors® Successfully Goes Live with Midwest Real Estate Data
5
Update on Parys Mountain Optimisation Study

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 January 2019 01:51:10
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190121.1 - EUROWEB2 - 2019-01-23 02:51:10 - 2019-01-23 01:51:10 - 1000 - Website: OKAY